SUDA Pharmaceuticals Ltd's (ASX:SUD) (FRA:E4N) Dr Michael Baker discusses with Proactive's Andrew Scott its first half FY21 developments which include securing TGA approval for its ZolpiMist insomnia treatment and receiving the patent for its anagrelide formation for the treatment of metastatic disease. The company ended the period to December 31, 2020, well-funded with cash at bank of $5.5 million off the back of successful capital raises during the half year of $6.85 million to sophisticated and new investors.
SUDA Pharmaceuticals focused on commercialising its lead ZolpiMist product
